UK biotech companies raised £552 million in equity financing in Q1 2026, marking an 18% increase from the prior quarter, with venture capital up 17%. The capital was distributed among more firms than ...

With an uptick and increasingly even spread of capital across the space, the BIA’s Martin Turner is optimistic for British ...

A science campus is strengthening its research capabilities with the launch of a specialist facility designed to support ...

Financing for UK biotech jumped 17% at the start of the year from the previous quarter, with equity financing passing the ...

-Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over year growth- -Reiterating financial guidance of approximately $20 million ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

The funding momentum that was building at the end of 2025 was maintained in the first quarter (Q1) of 2026, with a rebound in venture capital (VC) investment in U.K. biotech. Overall investment in the ...

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

The United Kingdom aims to boost its life sciences profile as Aviva Capital Partners and Socius unveiled plans for a £1 billion ($1.3 billion) cancer research and manufacturing hub on the outskirts of ...

Novartis AG will pay UK biotech Relation Therapeutics Ltd. as much as $1.7 billion to help find drug targets to treat allergic diseases. The Swiss drugmaker will pay $55 million upfront to combine its ...

Josh is the Global Real Estate transaction lead for GSK, focusing on aligning real estate strategies with business objectives and transforming the portfolio to create the World’s healthiest workplaces ...